Tilray(US:TLRY)2026-01-08 22:32Financial Data and Key Metrics Changes - The company reported a record Q2 net revenue of $218 million, with an adjusted EBITDA of $8.4 million and a reported EPS loss of $0.02, reflecting a significant improvement in performance metrics [4][22]. - The net loss for the quarter was $43.5 million, a 49% improvement year-over-year compared to $85.3 million, with cash flow used in operations reduced to $8.5 million from $40.7 million last year [26][27]. Business Line Data and Key Metrics Changes - Cannabis net revenue increased to $67.5 million, driven by a 36% increase in international cannabis revenue and a 6% increase in Canadian adult-use cannabis [22][23]. - Beverage revenue totaled $50.1 million, impacted by headwinds in the craft beer segment, while distribution revenue grew by 26% year-over-year to $85.3 million [11][23]. - Wellness revenue remained flat year-over-year at $14.6 million, with challenges in the club retail channel being addressed [24]. Market Data and Key Metrics Changes - The international cannabis business saw a 51% sequential growth, reaching $20 million, marking one of the strongest quarters to date despite ongoing regulatory challenges [9][10]. - In Canada, the adult-use medical sales channel net of excise tax grew to $46 million, with recreational cannabis sales increasing by 6% [12][22]. Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and cash position to capitalize on strategic opportunities in a rapidly evolving regulatory environment, particularly in the U.S. cannabis market [5][28]. - Tilray is focused on expanding its pharmacy reach in Germany and tripling its medical cannabis distribution footprint in fiscal 2026 [10][11]. - The company emphasizes the importance of modernizing Canadian cannabis regulations to maintain its competitive edge in the global market [14][15]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the second half of fiscal 2026 and beyond, citing a diversified platform and improving fundamentals [21][28]. - The company is prepared for potential regulatory changes in the U.S. and anticipates that cannabis rescheduling will lead to a federally compliant medical cannabis framework [7][8]. Other Important Information - The company operates more than 40 brands in over 20 countries and is a leader in various segments, including cannabis, craft beer, and wellness products [5][6]. - The company has a strong cash position of approximately $292 million, providing flexibility for strategic investments [5][27]. Q&A Session Summary Question: What can the industry do to improve the regulatory outcome regarding the intoxicating hemp ban? - Management is working with legislators to extend the deadline or modify regulations to allow for a regulated amount of milligrams to be sold nationally [33][34]. Question: Can you quantify how much supply was held back from the Canadian market? - Approximately $5 million worth of supply was held back, which will be redeployed into higher-margin international markets [37][38]. Question: How much of the Canadian adult-use cannabis growth was volume versus price mix? - The growth was primarily driven by demand and new distribution, with a slight market share gain despite challenges [45][46]. Question: What are the expectations for growth within the Canadian market? - Management anticipates mid- to high single-digit growth, focusing on premium products and new product launches [57][58]. Question: Can you provide more color on the CC Pharma business and its distribution reach? - The company aims to triple its distribution reach and is focused on leveraging its sales organization to sell more medical cannabis in Germany [67][68].